By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nektar Therapeutics (CA) 

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco  California  94158  U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300


SEARCH JOBS

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™(naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly-owned mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development. NKTR-171, a wholly-owned new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer. In hemophilia, BAX 855, a longer-acting PEGylated Factor VIII therapeutic is in Phase 3 development conducted by partner Baxter. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

The company was founded in 1990 and is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.




Key Statistics


Email: nektar@nektar.com
Ownership: Public

Web Site: Nektar Therapeutics
Employees: 429
Symbol: NKTR
 









Company News
Nektar Therapeutics (NKTR)' President And CEO, Howard W. Robin, To Present At The Jefferies and Co. 2015 Global Healthcare Conference In New York City 5/28/2015 7:58:35 AM
Nektar Therapeutics (NKTR) Reports Financial Results For The First Quarter Of 2015 5/1/2015 8:13:29 AM
Nektar Therapeutics (NKTR) To Announce Financial Results For The First Quarter 2015 On Thursday, April 30, 2015, After Close Of U.S.-Based Financial Markets 4/27/2015 10:10:19 AM
Nektar Therapeutics (NKTR) To Present At The 14th Annual Needham Healthcare Conference 4/14/2015 9:25:15 AM
Nektar Therapeutics (NKTR) Announces Receipt Of $100 Million Milestone Payment From AstraZeneca PLC (AZN) 4/2/2015 8:06:20 AM
Nektar Therapeutics (NKTR) Release: MOVANTIK (Naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US 3/31/2015 7:38:45 AM
Nektar Therapeutics (NKTR) Cancer Drug Improves Survival But Misses Primary Endpoint, As Watchers Worry 3/17/2015 2:25:30 PM
Nektar Therapeutics (CA) (NKTR) Reports Fourth Quarter and Year-End 2014 Financial Results 2/25/2015 9:21:57 AM
Nektar Therapeutics (CA) (NKTR) Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain 2/25/2015 9:13:05 AM
Nektar Therapeutics (CA) (NKTR) To Announce Financial Results For The Fourth Quarter And Year-Ended 2014 On Tuesday, February 24, 2015, After Close Of U.S.-Based Financial Markets 2/18/2015 12:31:31 PM
12345678910...
//-->